Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver
DOI:
https://doi.org/10.5912/jcb731Keywords:
biologics, data exclusivity protection, Trans-Pacific Partnership Trade AgreementAbstract
Biopharmaceutical research and development is overwhelmingly focused in the U.S. becasue here it is incentivized and encouraged through a robust intellectual property rights protection environment. Across the board, the United States provides the most comprehensive, effective intellectual property rights protections for biopharmaceuticals. As a result, the industry locates here, researches here, and thrives here. With an acknowledgement of the importance of intellectual property rights as well as the wider benefits of biopharmaceutical research and development, it's tremendously disappointing that the recently negotiated Trans-Pacific Partnership (TPP) Trade Agreement fails to deliver sufficient IP protections for biologics. This article explores the importance of a rigorous intellectual property environemtn for the biopharmaceutical industry through an examination of the importance of data exclusivity provisions. Such protection is critical as the number, complexity and cost of clinical trials increases. Technology inevitably evolves faster than the legal architecture that surrounds it. As technology evolves, making the development of new biologic vaccines and therapies possible, society's commitment to incentivize innovation and protect it must be enshrined in the intellectual property protections of agreements such as the TPP.References
Adams, C.P. and V.V. Brantner. “Spending on New Drug Development,†Health Economics, vol.19, no.2, February 2010, pp.130-141.
Battelle. “Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies,†March 2015. Available at: http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf
Budish, Eric, Benjamin N. Roin, and Heidi Williams. “Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,†American Economic Review, vol.105, no.7, 2015, pp.2044-2085.
Calmes, Jackie. “Utah Senator, Crucial Ally for the Pacific Rim Trade Deal, Is Now Its Main Hurdle,†New York Times, 12 November 2015. Available at: http://www.nytimes.com/2015/11/13/us/politics/utah-senator-crucial-ally-for-the-pacific-rim-trade-deal-is-now-its-main-hurdle.html
Cohen, Wesley M., Richard R. Nelson, and John Walsh. “A First Look at the Results of the 1994 Carnegie Mellon Survey of Industrial R&D in the United States,†unpublished manuscript, 28 February 1996.
Cohn, Meredith. “Industry funds six times more clinical trials than feds, research shows,†The Baltimore Sun, 15 December 2015. Available at: http://www.baltimoresun.com/health/bs-hs-trial-funding-20151214-story.html
Desmon, Stephanie. “Industry-financed clinical trials on the rise as number of NIH-funded trials falls: Researchers raise concerns about trends in research funding as commercial ventures run six times more trials than academic investigators,†The HUB at Johns Hopkins, 16 December 2015. Available at: http://hub.jhu.edu/2015/12/15/industry-funded-clinical-trials-may-threaten-objectivity
DiMasi, Joseph A. and Henry G. Grabowski. “The Costs of Biopharmaceutical R&D: Is Biotech Different?†Managerial and Decision Economics, vol.28, 2007.
Getz, K.A., R.A. Campo, and K.I. Kaitin. “Variability in Protocol Design Complexity by Phase and Therapeutic Area.†Drug Information Journal, 2011, vol.45, no.4, pp. 413–420.
Grabowski H.G. and J.M. Vernon. “A New Look at the Returns and Risks to Pharmaceutical R&D,†Management Science, vol.36, no.7, 1990, p.804-821.
Grabowski, H.G., J.M. Vernon and J.A. DiMasi. “Returns on research and development for 1990s new drug introductions,†Pharmacoeconomics, vol.20, suppl.3, 2002, pp.11-29.
Grabowski, Henry, Genia Long and Richard Mortimer, “Data Exclusivity for Biologics,†Nature Reviews: Drug Discovery, January 2011, vol.10, pp.15-25. Available at: http://www.nature.com/nrd/journal/v10/n1/suppinfo/nrd3277.html
Levin, R.C., A.K. Klevorick, R.R. Nelson, and S.G. Winter. “Appropriating the Returns from Industrial Research and Development,†Brookings Papers on Economic Activity, (Special Issue), no.3, 1987, pp.783-831.
Lybecker, Kristina. “IP Protection for Biologics in the TPP: Trading Away Future Treatments and Cures,†IPWatchDog, 26 October 2015. Available at: http://www.ipwatchdog.com/2015/10/26/ip-protection-for-biologics-in-the-tpp-trading-away-future-treatments-and-cures/id=62692/
Mansfield, Edwin. “Patents and Innovations: An Empirical Study,†Management Science, vol.32, no.2, February 1986, pp.173-181.
Mansfield, Edwin, Mark Schwartz, and Sam Wagner. “Imitation Costs and Patents: An Empirical Study,†Economic Journal, vol.91, no.364, December 1981, pp.907-918.
Mossinghoff, Gerald J. “Encouraging Invention and Innovation: The Key to Human Progress,†PhRMA: Pharmaceutical Research and Manufacturers of America, World Wide Web Posting: January 1998. [www.phrma.org/issues/inter1.htm]
Mossinghoff, Gerald J., and Thomas Bombelles. “The Importance of Intellectual Property Protection to the American Research-Intensive Pharmaceutical Industry,†Columbia Journal of World Business, vol.XXXI, no.1, Spring 1996, pp.38-48.
Mossinghoff, Gerald J. “Research-Based Pharmaceutical Companies: The Need for Improved Patent Protection Worldwide,†Journal of Law and Technology, vol.2, no.2, 1987, pp.307-324.
Peretz, S. Michael. “Pharmaceuticals in the Third World: The Problem from the Suppliers’ Point of View,†World Development, vol.11, no.3, March 1983, pp.259-264.
PhRMA (Pharmaceutical Research and Manufacturers of America). “2015 Biopharmaceutical Research Profile†online post, 2015. Available at: http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf
PhRMA(Pharmaceutical Research and Manufacturers of America). “Biopharmaceuticals in Perspective,†Spring 2013. Available at: http://www.slideshare.net/PhRMA/phrma-chart-pack-april-2013?related=1
Roy, A.S.A. “Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials,†Project RDA Report, 24 April 2012. Available at: https://www.manhattan-institute.org/html/stifling-new-cures-true-cost-lengthy-clinical-drug-trials-6013.html
Santoro, Michael. “Pfizer: Global Protection of Intellectual Property,†Harvard Business School Case Study N9-392-073, April 6, 1995.
Scherer, F.M. “The Economic Effect of Compulsory Patent Licensing,†Monograph Series in Finance and Economics, New York, NY: New York University, 1997.
Smith, N. Craig. “Note on Pharmaceutical marketing Practices In the Third World,†Harvard Business School Case Study N9-590-032, December 16, 1990.
Smith, N. Craig. “Ciba-Geigy Pharmaceuticals: Pharma International,†Harvard Business School Case Study N9-589-108, December 14, 1990.
Taylor, C.T., and Z. A. Silberston. The Economic Impact of the Patent System. Cambridge, UK: Cambridge University Press, 1973.
Tocker, Edwin. “A Chemical Industry Perspective,†Chapter 13 in Intellectual Property Rights and Capital Formation in the Next Decade, Charls E. Walker and Mark A. Bloomfield, eds., pp.151-162, Landham, MD: University Press of America, Inc., 1988.
